Cytogenetic Features of Elderly Turkish Myelodysplastic Syndrome Patients

Objective: Myelodysplastic syndrome (MDS) represents one of the most frequent and serious hematologic diseases among the elderly. Chromosomal abnormalities have been detected in 23%-78% patients with MDS. We analyzed the cytogenetics of elderly MDS patients in Turkey. Materials and Methods: Data on patients (>65 years old) diagnosed with primary MDS from 2011 to 2013 were retrospectively collected from Erciyes University. Chromosome analysis was performed in 54 patients using conventional karyotyping and fluorescence in situ hybridization (FISH). Results: Of the 54 patients recruited, karyotype abnormalities were found in 8 (15%) of 54 cases, among which, 5 (9%) were Trisomy 8 and 3 (6%) were del 5q. Conclusion: The incidence of chromosomal abnormalities in elderly Turkish MDS patients was lower than that reported in the literature. Although the pathogenesis of MDS is still poorly understood, environmental and biological factors could induce mechanisms that are associated with diverse karyotypes and variable frequencies of chromosomal abnormalities.

Kaynakça

Shadman M, Deeg HJ. Hematopoietic Cell Transplantation for Older Patients with MDS. Mediterr J Hematol Infect Dis 2014; 6(1): e2014056. [CrossRef]

Wang H, Wang X, Xu X, Lin G. Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multi- center study. Ann Hematol 2010; 89(6): 535-44. [CrossRef]

Nimer SD. Myelodysplastic syndromes. Blood 2008; 111(10): 4841- 51. [CrossRef]

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodys- plastic syndromes. Blood 2012; 120(12): 2454-65. [CrossRef]

Panani AD. Cytogenetic findings in adult greek myelodysplastic syn- drome patients: predominance of single trisomy 8. In Vivo 2006; 20(1): 115-8.

Wang H, Wang XQ, Xu XP, Lin GW. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome. Cancer Genet Cy- togenet 2010; 196(2): 159-66. [CrossRef]

Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Giardini I, Rocca B, et al. Clinical relevance of cytogenetics in myelodys- plastic syndromes. Ann N Y Acad Sci 2006; 1089: 395-410. [CrossRef]

Cai Y, Qin YW, Wang C, Yang J, Yan SK. [Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical sig- nificance]. Zhonghua Xue Ye Xue Za Zhi 2007; 28(1): 6-10.

Romeo M, Chauffaille Mde L, Silva MR, Bahia DM, Kerbauy J. Com- parison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. Leuk Res 2002; 26(11): 993-6. [CrossRef]

Shen Y, Xue Y, Li J, Pan J, Wu Y, Chen S. [Detection of common chromosome abnormalities in myelodysplastic syndrome with a panel fluorescence in situ hybridization]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003; 20(2): 160-3.

Haase, D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008; 87(7): 515-26. [CrossRef]

West RR, Stafford DA, White AD, Bowen DT, Padua RA. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood 2000; 95(6): 2093-7.

Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplas- tic syndrome. Best Pract Res Clin Haematol 2004; 17(4): 543-57. [CrossRef]

Vardiman JW, Harris NL, Brunning RD. The World Health Organi- zation (WHO) classification of the myeloid neoplasms. Blood 2002; 100(7): 2292-302. [CrossRef]

Rashid A, Khurshid M, Shaikh U, Adil S. Chromosomal abnormali- ties in primary myelodysplastic syndrome. J Coll Physicians Surg Pak 2014; 24(9): 632-5.

Gonzalez Garcia JR, Meza-Espinoza JP. Use of the International System for Human Cytogenetic Nomenclature (ISCN). Blood 2006; 108(12): 3952-3. [CrossRef]

Dakshinamurthy AG, Novitzky N, Bharadwaj R, Prakhya BM. Cyto- genetic analysis of 52 Indian patients with de novo myelodysplastic syndromes-a comparative analysis of results with reports from Asia. Ann Hematol 2005; 84(5): 298-303. [CrossRef]

Li L, Liu XP, Nie L, Yu MH, Zhang Y, Qin TJ, et al. Unique cytogenet- ic features of primary myelodysplastic syndromes in Chinese patients. Leuk Res 2009; 33(9): 1194-8. [CrossRef]

Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hil- debrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110(13): 4385-95. [CrossRef]

20. Washington LT, Doherty D, Glassman A, Martins J, Ibrahim S, Lai R. Myeloid disorders with deletion of 5q as the sole karyotypic abnor-mality: the clinical and pathologic spectrum. Leuk Lymphoma 2002; 43(4): 761-5. [CrossRef]

21. Crescenzi B, La Starza R, Romoli S, Beacci D, Matteucci C, Barba G, et al. Submicroscopic deletions in 5q- associated malignancies. Hae-matologica 2004; 89(3): 281-5.

22. Pedersen B. MDS and AML with trisomy 8 as the sole chromo-some aberration show different sex ratios and prognostic pro-files: a study of 115 published cases. Am J Hematol 1997; 56(4): 224-9. [CrossRef]

23. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 2010; 116(9): 2174-9.[CrossRef]

Kaynak Göster